A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here are two cash-producing companies that excel at turning cash into shareholder value and one that may struggle to keep up.
One Stock to Sell:
US Foods (USFD)
Trailing 12-Month Free Cash Flow Margin: 2.1%
With a fleet of over 6,500 trucks delivering everything from fresh produce to frozen entrées, US Foods (NYSE: USFD) is a major foodservice distributor that supplies food products and services to approximately 250,000 restaurants, healthcare facilities, hotels, and educational institutions across the United States.
Why Do We Pass on USFD?
- Products are reaching more customers as its unit sales averaged 2.4% growth over the past two years
- Responsiveness to unforeseen market trends is restricted due to its substandard operating margin profitability
- Poor free cash flow margin of 2.5% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends
US Foods’s stock price of $85.17 implies a valuation ratio of 17x forward P/E. Dive into our free research report to see why there are better opportunities than USFD.
Two Stocks to Watch:
BioMarin Pharmaceutical (BMRN)
Trailing 12-Month Free Cash Flow Margin: 23.7%
Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ: BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.
Why Does BMRN Stand Out?
- Offerings and unique value proposition resonate with customers, as seen in its above-market 14.5% annual sales growth over the last two years
- Market share is on track to rise over the next 12 months as its 27% projected revenue growth implies demand will accelerate from its two-year trend
- Free cash flow margin grew by 22.4 percentage points over the last five years, giving the company more chips to play with
At $53.70 per share, BioMarin Pharmaceutical trades at 2.5x forward price-to-sales. Is now the time to initiate a position? See for yourself in our in-depth research report, it’s free.
Sezzle (SEZL)
Trailing 12-Month Free Cash Flow Margin: 51%
Founded in 2016 as an alternative to traditional credit cards for younger shoppers, Sezzle (NASDAQ: SEZL) provides a payment platform that allows consumers to split purchases into four interest-free installments over six weeks at participating retailers.
Why Is SEZL a Good Business?
- Market share has increased this cycle as its 67.4% annual revenue growth over the last two years was exceptional
- Earnings growth has trumped its peers over the last one years as its EPS has compounded at 65% annually
Sezzle is trading at $102.01 per share, or 18.4x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
